Mondher Mahjoubi was appointed Chief Executive Officer and Chairman of the Executive Board on December 30, 2016.
Dr. Mahjoubi is also currently an independent board member and Chairman of the Board of Directors at PDC*line Pharma, a clinical stage biotech company developing a novel class of anticancer vaccines.
Prior to joining Innate Pharma, Dr. Mahjoubi led AstraZeneca’s oncology therapy area franchise, playing an instrumental role in driving its oncology strategy from 2013-2016. Prior to that role, he served as the Senior Vice President of global product strategy in oncology at Genentech from 2010-2013. He also previously various held Global & US marketing and medical affairs positions at Roche, Sanofi-Aventis and Rhone Poulenc Rorer.
Dr. Mahjoubi is trained as a medical oncologist, holds a M.D. from the University of Tunis and certifications in Medical Oncology from the University of Tunis and University of Paris Sud and in Clinical Research and Methodology from the University of Lariboisiere-Saint Louis-Paris. He is a member of the American Society of Clinical Oncology and European Society of Medical Oncology.